frankw17

Author Archives

Tax-Free Oil Wealth

This is a request about an opinion re. ”Tax-Free Oil Wealth: The Perfect Retirement Plan” currently being pitched by Brian Hicks at Wealth Daily. He makes this thing sound like a phenomenal investment, tax free, that will make you incredibly wealthy. This reminds me of that old adage ”if it sounds to good to be […]

Tax-Free Oil Wealth

Travis, is a request about an opinion re. ”Tax-Free Oil Wealth: The Perfect Retirement Plan” currently being pitched by Brian Hicks at Wealth Daily. He makes this thing sound like a phenomenal investment, tax free, that will make you incredibly wealthy. This reminds me of that old adage ”if it sounds to good to be […]

Recent Author Comments

On What's "The Pot Stock of the Decade" pitched by The Wealth Advisory?
rickla57 and Travis, even if the banks enter the business of providing loans for cannabis companies, it will more than likely be quite some time in the future. That is to say, when have you ever seen the banks jump into providing a fledgling industry with [...]
On Ray Blanco's "Halo-Fi" -- What's his teased "Death to Cable" stock?
Interesting article Travis, however I'm not sure when OneWeb will be public. I checked my source for IPO's and I couldn't find anything re. them even filing for an IPO as of today. Furthermore, there was no information with respect to them withdrawing e[...]
On Friday File: Stop Losses and Big Quarters
Love the author icon Travis. Regards, Frank[...]
On Biotech Discussion... continued
NP in $AFMD, although I wish still had one. Currently trading at $4.10 after hours, up 156.25% on 2.5M+ shares. The volume is more than 10X the volume during the regular trading session. Regards, Frank[...]
On What's "The Pot Stock of the Decade" pitched by The Wealth Advisory?
Good article Travis. I'm glad I followed you into IIPR 6 months ago. Also, I'd like to echo the comment from above. My investment in SG as an Irregular was the best financial decision I've made in 50 years! Regards, Frank[...]
On Biotech Discussion... continued
Long $AUPH: Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) was given a new $18.00 price target on by analysts at Cantor Fitzgerald on Saturday. They now have a “buy” rating on the stock. 238.3% upside from the current price of $5.32. Aurinia Pharmac[...]
On Alzheimer’s Disease 2018: The Lay of the Land
Great article Michael. AD continues to be 1 of the biggest mysteries of life, especially to someone such as myself who'se family has been very susceptible to it. Thank you. Regards, Frank[...]
On Oncotutorial
Long $BLPH: 8/9) Bellerophon Therapeutics (BLPH) Rating Reiterated by HC Wainwright (americanbankingnews.com): Bellerophon Therapeutics (NASDAQ:BLPH) was given a new $3.00 price target on by HC Wainwright ( ) (analyst A. Fein). They now have a "buy" rat[...]
On Friday File: Buys in Small Tech and Baby Berkshires
$TSLA; another great article Travis. Thank you. David, I'm not sure what your source is for those Jan,2020 155 puts, but Schwab shows them at $17.20 bid, $18.10 ask and a midpoint of $17.65. Therefore, realistically 5 of these puts would indeed cost [...]
On Microblog: Club house for Politics, Religion, etc. (volume 8)
Great observations and questions hn. Thanks. Regards, Frank[...]
On Microblog: Club house for Politics, Religion, etc. (volume 8)
Great post hn! I would also include CNBC in that suspect group. Hopefully it all gets resolved in some sort of legal fashion. BTW, glad to see this forum still exist! Regards, Frank[...]
On Biotech Discussion... continued
Thanks Ben. I wondered why we hadn't heard from him in some time. Regards, Frank[...]
On Biotech Discussion... continued
Long ESPR: Esperion Therapeutics (NASDAQ:ESPR) Target N V Biotech (Major Shareholder) Buy 50,000 shares @ $39.48 $1,974,000.00 6/29/2018 Regards, Frank[...]
On Biotech Discussion... continued
Long ZFGN: Zafgen (NASDAQ:ZFGN) is now covered by analysts at Piper Jaffray Companies. They set an "overweight" rating and a $18.00 price target on the stock. 77.2% upside from the current price of $10.16. Regards, Frank[...]
On Biotech Discussion... continued
$AKAO NP; Ben, this appears to be good news, but you would never know it from the market's reaction. The stock is down $2.40, a 20% drop on more than 3X average daily volume. Go figure? Regards, Frank[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
Long $MEIP;MEI Pharma (NASDAQ:MEIP) was upgraded by analysts at Wells Fargo & Co from a "market perform" rating to an "outperform" rating. current price of $4.90. NP $MRNS;Marinus Pharmaceuticals (NASDAQ:MRNS) is now covered by analysts at LADENBURG THALM[...]
On Solved: Robinson's "Shape-Shifting 'Smart Metal'" Tease for 4,000% Gains?
Good article Travis, but Robinson is gilding the lily. There has been talk of gallium arsenide overtaking silicon for well over 40 years that I'm aware of, but it has never happened and anyone who thinks this investment will achieve a 45,798% sales surge[...]
On Friday File: Premier, Estre, Naspers, NVIDIA and gold coins
Travis, congratulations on your TTD investment. I wish I had followed you into it some time back. Regards, Frank[...]
On Microblog: Gold, Silver, Copper, and Hard Assets…Fall 2017
Long $IVPAF and $CTQEF; Great post HN. Thanks. Regards, Frank[...]
On Biotech Discussion... continued
$AKAO, NP; Good prognostication STM, as $AKAO traded from a low of $10.10 up to a high of $12.40 today. Furthermore it's up $.44 and the last trade was $11.50 at 6:21PM EST. Regards, Frank[...]

This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

Connect with Travis

website designed by Gravity Switch